Risk of Maculopathy in Tamoxifen Users: Drug Exposure and Risk Factors
Abstract Tamoxifen, a pivotal therapy for hormone receptor-positive breast cancer, is known for its efficacy in reducing breast cancer recurrence and mortality. However, concerns about potential ocular complications, particularly maculopathy, have emerged. This study aims to investigate the risk and associated factors of diverse macular conditions in tamoxifen users, considering drug exposure, demographics, and systemic diseases. A nationwide cohort of tamoxifen users, comprised of 14,267 tamoxifen users, was analyzed using the Health Insurance Review and Assessment (HIRA) database in South Korea. Demographic and clinical characteristics were examined, and the cumulative incidence of macular diseases was stratified by age and cumulative tamoxifen dosage. Hazard ratios were calculated for risk factors, including age, sex, and systemic diseases affecting drug metabolism. Cumulative incidences of overall macular diseases, other maculopathy excluding common macular diseases, and macular edema were 26.4%, 11.4%, and 6.5%, respectively. The risk increased with age and cumulative tamoxifen dosage. Significant risk factors included age, sex, diabetes, hypertension, and kidney disease whereas dyslipidemia and liver disease showed no significant association with the macular conditions. Tamoxifen-induced maculopathy poses a concern for prescribing physicians and ophthalmologists, and this study provides valuable insights into its risk and risk factors. The complex interplay between age, cumulative tamoxifen dosage, and systemic diseases highlights the need for vigilant monitoring and screening strategies. This study may contribute to evidence-based guidelines for tamoxifen maculopathy screening, emphasizing the importance of considering multiple factors for recommendation on screening timing and frequency..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ResearchSquare.com - (2024) vom: 13. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kwon, Hyeon Yoon [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-3915748/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA042502098 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA042502098 | ||
| 003 | DE-627 | ||
| 005 | 20240214151412.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240214s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-3915748/v1 |2 doi | |
| 035 | |a (DE-627)XRA042502098 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-3915748/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kwon, Hyeon Yoon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk of Maculopathy in Tamoxifen Users: Drug Exposure and Risk Factors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Tamoxifen, a pivotal therapy for hormone receptor-positive breast cancer, is known for its efficacy in reducing breast cancer recurrence and mortality. However, concerns about potential ocular complications, particularly maculopathy, have emerged. This study aims to investigate the risk and associated factors of diverse macular conditions in tamoxifen users, considering drug exposure, demographics, and systemic diseases. A nationwide cohort of tamoxifen users, comprised of 14,267 tamoxifen users, was analyzed using the Health Insurance Review and Assessment (HIRA) database in South Korea. Demographic and clinical characteristics were examined, and the cumulative incidence of macular diseases was stratified by age and cumulative tamoxifen dosage. Hazard ratios were calculated for risk factors, including age, sex, and systemic diseases affecting drug metabolism. Cumulative incidences of overall macular diseases, other maculopathy excluding common macular diseases, and macular edema were 26.4%, 11.4%, and 6.5%, respectively. The risk increased with age and cumulative tamoxifen dosage. Significant risk factors included age, sex, diabetes, hypertension, and kidney disease whereas dyslipidemia and liver disease showed no significant association with the macular conditions. Tamoxifen-induced maculopathy poses a concern for prescribing physicians and ophthalmologists, and this study provides valuable insights into its risk and risk factors. The complex interplay between age, cumulative tamoxifen dosage, and systemic diseases highlights the need for vigilant monitoring and screening strategies. This study may contribute to evidence-based guidelines for tamoxifen maculopathy screening, emphasizing the importance of considering multiple factors for recommendation on screening timing and frequency. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Kim, Jiyeong |4 aut | |
| 700 | 1 | |a Ahn, Seong Joon |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2024) vom: 13. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:13 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-3915748/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 13 |c 02 | ||